查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1888562

美國阿茲海默症診斷影像市場規模、佔有率和趨勢分析報告：按診斷影像方式、最終用途和細分市場預測（2025-2033 年）

U.S. Alzheimer's-linked Imaging Market Size, Share & Trends Analysis Report By Imaging Modality (Positron Emission Tomography, Magnetic Resonance Imaging, Single Photon Emission Computed Tomography), By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

2024 年美國阿茲海默症相關影像診斷市場規模估計為 44.9 億美元，預計到 2033 年將達到 69 億美元。

預計2025年至2033年複合年成長率將達5.1%。市場成長的主要促進因素是美國阿茲海默症症患者人數的不斷增加。根據美國國家醫學圖書館（NLH）2024年的數據，目前約有690萬65歲及以上的美國患有老年失智症失智症，如果到2060年沒有突破性治療方法問世，這一數字可能達到1380萬。阿茲海默症目前是美國老年人第五大死因，顯示其對公共衛生的影響日益加劇。

隨著阿茲海默症患者病率的上升，對早期診斷和持續監測的需求也日益成長。這為阿茲海默症症影像技術和服務領域的投資與創新創造了巨大的機會。各國政府和公共衛生機構也積極支持這一趨勢。例如，美國疾病管制與預防中心（CDC）的阿茲海默症計畫致力於提高公眾意識、促進早期發現並提升診斷能力。這些努力共同推動了美國診斷基礎設施的擴建、影像服務的可及性提升以及腦部疾病影像技術的進步。

此外，拉什大學的一項研究發現，美國阿茲海默症率有顯著的區域差異，佛羅裡達州和馬裡蘭州等州的盛行率最高。這些縣級差異受多種因素影響，例如人口年齡分佈、社會經濟經濟狀況、醫療保健資源以及生活方式習慣。

在美國，技術創新持續推動阿茲海默症影像產業的成長。目前，磁振造影（MRI）、正子斷層掃描（PET）和單光子發射電腦斷層掃描（SPECT）等技術是診斷和後續觀察阿茲海默症的重要工具。 MRI 可提供清晰的解剖影像，PET 可視覺化和量化BETA-澱粉樣蛋白斑塊和Tau蛋白纖維纏結，而 SPECT 則用於評估腦血流和功能障礙。這些技術在美國各地的醫院和門診影像中心被廣泛用於診斷和治療方案製定。

人工智慧輔助診斷技術正在改變美國阿茲海默症診斷影像市場。例如，梅奧診所的StateViewer人工智慧系統僅需一次氟代脫氧葡萄糖正子斷層掃描（FDG-PET）即可檢測出包括阿茲海默症在內的九種失智症。透過提高診斷準確率和縮短解讀時間，人工智慧正在擴大先進診斷技術的普及範圍，並增強臨床醫生對早期準確診斷的信心。

此外，該市場擁有強而有力的政府支持和戰略規劃。例如，隸屬於美國衛生與公眾服務部的國家老齡研究所 (NIA)統籌所有聯邦政府應對阿茲海默症(AD) 及相關失智症的活動。由《國家阿茲海默阿茲海默症行動法案》(NAPA) 設立的《國家阿茲海默症症計畫》旨在加速研究和治療，並在許多相關領域加強對患者、家屬和看護者的支持。該計劃的主要重點是改善早期檢測、提升患者照護和看護者體驗、推廣有效的護理模式，以及推進診斷和治療方面的研究。這些措施體現了美國政府致力於加強阿茲海默症護理基礎設施和研究能力、促進先進診斷和影像技術的應用，以及支持阿茲海默症症影像市場發展的決心。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國阿茲海默症影像診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關及附隨市場展望
  • 市場動態
  • 美國阿茲海默症相關影像診斷市場分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析

第4章美國阿茲海默症診斷影像市場：診斷影像方式的估計與趨勢分析

  • 美國阿茲海默症診斷影像市場：診斷影像方式變化分析
  • 美國阿茲海默症診斷影像市場：按診斷成像方式分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 正子斷層掃描（PET）
    • 澱粉樣蛋白正子斷層掃描（PET）
    • Tau正子斷層掃描
    • FDG正子斷層掃描
  • 磁振造影（MRI）
    • 結構性磁振造影（MRI）
    • 高階磁振造影（MRI）
  • 單光子發射電腦斷層掃描（SPECT）
  • 其他

第5章美國阿茲海默症診斷影像市場：終端用戶估算與趨勢分析

  • 美國老年失智症診斷影像市場：終端用途差異分析
  • 美國老年失智症診斷影像市場：按最終用途分類的展望
  • 市場規模、預測與趨勢分析（2021-2033）
  • 醫院和診所
  • 診斷影像中心
  • 受託研究機構（CRO）
  • 其他

第6章 競爭情勢

  • 市場參與企業分類
  • 主要企業簡介
    • GE Healthcare
    • Siemens Healthineers AG
    • Life Molecular Imaging（LMI）
    • Eli Lilly and Company
    • SOFIE Biosciences
    • Lantheus Holdings, Inc.
    • Jubilant Radiopharma
    • Brainreader A/S/Neuroreader
    • Koninklijke Philips NV
    • Alzevita
Product Code: GVR-4-68040-796-9

Market Size & Trends:

The U.S. Alzheimer's-linked imaging market size was estimated at USD 4.49 billion in 2024 and is projected to reach USD 6.90 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033. Market growth is mainly driven by the rising number of Alzheimer's cases across the country. According to the National Library of Medicine (NLH) (2024), around 6.9 million Americans aged 65 and older are currently living with Alzheimer's dementia, and this number could reach 13.8 million by 2060 if no breakthrough occurs. Alzheimer's is now the fifth-leading cause of death among older adults in the U.S., highlighting its growing public health impact.

As the prevalence of the disease increases, demand for early diagnosis and continuous monitoring is rising. This is creating strong opportunities for investment and innovation in Alzheimer's-related imaging technologies and services. Government and public health agencies are also supporting this trend. For instance, the Centers for Disease Control and Prevention's (CDC) Alzheimer's disease Program promotes awareness, early detection, and diagnostic readiness. Together, these initiatives are helping expand diagnostic infrastructure, improve access to imaging services, and encourage technological advancements in brain-disease imaging across the U.S.

Furthermore, a study by Rush University highlighted significant regional differences in Alzheimer's disease prevalence across the U.S., with the highest rates observed in states such as Florida and Maryland. These county-level variations are influenced by factors such as population age distribution, socioeconomic conditions, healthcare accessibility, and lifestyle habits.

Technological advancements continue to drive the growth of the U.S. Alzheimer's-linked imaging industry. Currently used techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), are essential methods for the diagnosis and monitoring of Alzheimer's disease. MRI provides excellent anatomical imaging, PET allows visualization and quantification of amyloid-B plaques and tau tangles, and SPECT assesses cerebral blood flow and deficits in brain function. These techniques are routinely used to plan diagnosis and treatment in hospitals and outpatient imaging centers throughout the U.S.

AI-assisted diagnostics are transforming the U.S. Alzheimer's-linked imaging market. For instance, Mayo Clinic's StateViewer AI can detect nine types of dementia, including Alzheimer's, from a single fluorodeoxyglucose positron emission tomography (FDG-PET) scan. By enhancing accuracy and reducing interpretation time, AI expands access to advanced diagnostics and boosts confidence in early, precise detection across clinical settings.

Furthermore, strong governmental support and strategic planning exist within the market. For instance, the National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, oversees all federal activities aimed at addressing Alzheimer's disease (AD) and related dementias. The National Alzheimer's Project Act (NAPA) established the National Plan to Address Alzheimer's Disease, which aims to accelerate research, treatment, and support patients, families, and caregivers on various related topics. The plan's primary focus is on improving early detection, enhancing patient care and the caregiver experience, expanding effective care models, and advancing research in diagnosis and treatment. These initiatives reflect the U.S. government's commitment to strengthening Alzheimer's care infrastructure and research capacity, fostering wider adoption of advanced diagnostic and imaging technologies, and supporting growth in the Alzheimer's-linked imaging market.

U.S. Alzheimer's-linked Imaging Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Alzheimer's-linked imaging market report based on imaging modality, and end use:

  • Imaging Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Positron Emission Tomography
    • Amyloid Positron Emission Tomography
    • Tau Positron Emission Tomography
    • FDG- Positron Emission Tomography
  • Magnetic Resonance Imaging
    • Structural Magnetic Resonance Imaging
    • Advanced Magnetic Resonance Imaging
  • Single Photon Emission Computed Tomography
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Imaging Centers
  • Contract Research Organizations (CROs)
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Imaging Modality
    • 1.2.2. End Use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Imaging Modality Outlook
    • 2.2.2. End Use Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Alzheimer's-linked Imaging Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of Alzheimer's disease
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Governmental support and strategic planning
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Equipment Costs
      • 3.2.2.2. Limited Accessibility
  • 3.3. U.S. Alzheimer's-linked Imaging Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. U.S. Alzheimer's-linked Imaging Market: Imaging Modality Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Alzheimer-linked Imaging Market: Imaging Modality Movement Analysis
  • 4.3. U.S. Alzheimer-linked Imaging Market by Imaging Modality Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Positron Emission Tomography
    • 4.5.1. Positron Emission Tomography Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Amyloid Positron Emission Tomography (PET)
      • 4.5.2.1. Amyloid Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Tau Positron Emission Tomography
      • 4.5.3.1. Tau Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. FDG- Positron Emission Tomography
      • 4.5.4.1. FDG-Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Magnetic Resonance Imaging (MRI)
    • 4.6.1. Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Structural Magnetic Resonance Imaging (MRI)
      • 4.6.2.1. Structural Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Advanced Magnetic Resonance Imaging (MRI)
      • 4.6.3.1. Advanced Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Single Photon Emission Computed Tomography (SPECT)
    • 4.7.1. Single Photon Emission Computed Tomography (SPECT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Alzheimer's-linked Imaging Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Alzheimer-linked Imaging Market: End Use Movement Analysis
  • 5.3. U.S. Alzheimer-linked Imaging Market by End Use Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Hospitals & Clinics
    • 5.5.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Diagnostic Imaging Centers
    • 5.6.1. Diagnostic Imaging Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Contract Research Organizations (CROs)
    • 5.7.1. Contract Research Organizations (CROs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
  • 6.2. Key Company Profiles
    • 6.2.1. GE Healthcare
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Siemens Healthineers AG
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Life Molecular Imaging (LMI)
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Eli Lilly and Company
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. SOFIE Biosciences
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Lantheus Holdings, Inc.
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Jubilant Radiopharma
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. Brainreader A/S/ Neuroreader
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Koninklijke Philips N.V.
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Alzevita
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Alzheimer's-linked imaging market, by imaging modality, 2021 - 2033 (USD Million)
  • Table 4 U.S. Alzheimer's-linked imaging market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. Alzheimer's-linked imaging: market outlook
  • Fig. 9 U.S. Alzheimer's-linked imaging market competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. Alzheimer's-linked imaging market driver impact
  • Fig. 15 U.S. Alzheimer's-linked imaging market restraint impact
  • Fig. 16 U.S. Alzheimer's-linked imaging market strategic initiatives analysis
  • Fig. 17 U.S. Alzheimer's-linked imaging market: imaging modality movement analysis
  • Fig. 18 U.S. Alzheimer's-linked imaging market: imaging modality outlook and key takeaways
  • Fig. 19 Positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Amyloid positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Tau positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 FDG- positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Magnetic resonance imaging (MRI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Structural magnetic resonance imaging (MRI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Advanced magnetic resonance imaging (MRI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Single photon emission computed tomography (SPECT) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Alzheimer's-linked imaging market, end use outlook key takeaways (USD Million)
  • Fig. 29 U.S. Alzheimer's-linked imaging market end use movement analysis (USD Million), 2024 & 2033
  • Fig. 30 Hospitals & clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Diagnostic imaging centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Contract research organizations (CROs) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Participant categorization- U.S. Alzheimer's-linked imaging market
  • Fig. 35 Market share of key market players- U.S. Alzheimer's-linked imaging market